【Abstract】Objective  To evaluate the effectiveness, safety and economy of concordance and disconcordance guideline in the medication regimens of patients with advanced esophageal cancer in our hospital, and to provide a basis for standardizing the diagnosis and treatment of patients with advanced esophageal cancer. Methods  135 hospitalized patients with advanced esophageal cancer were divided into concordance guideline group (60 cases) and disconcordance guideline group (75 cases), and the average relative dose intensity of antitumor drugs was compared between the two groups. The efficacy and safety of antitumor drug treatment were compared according to the response evaluation criteria in solid tumors and common terminology criteria adverse events. The hospitalization cost, drug cost and antitumor drug cost were analyzed to compare the economy of antitumor drug treatment. Results  The average relative dose intensity, objective response rate, disease control rate and the incidence of adverse drug reaction in disconcordance guideline group were greater than those in concordance guideline group, but there were no statistically significant differences (P>0.05). The cost of hospitalization, medicine and anti-tumor drugs of disconcordance guideline group were greater than those of concordance guideline group (P<0.001) significantly. Conclusion  There were no significant differences in the safety and effectiveness between the concordance and disconcordance guideline groups, but the economy of the concordance guideline group was  better than that of disconcordance guideline group.

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

2. Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics[J]. Cancer Commun (Lond), 2019, 39(1): 22. DOI: 10.1186/s40880-019-0368-6.

3. 刘晓川，左小平，昌伟，等. 信迪利单抗联合化疗治疗复发晚期食管癌临床观察[J]. 中国药师, 2022, 25(5): 841-845. [Liu XC, Zuo XP, Chang W, et al. Clinical observation of sintilimab combined with chemotherapy in the treatment of recurrent advanced esophageal cancer[J]. China Pharmacist, 2022, 25(5): 841-845.] DOI: 10.19962/j.cnki.issn1008-049X. 2022.05.016.

4. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI: 10.3322/caac.21338.

5. Peng Z, Wei J, Wang F, et al. Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as firstline therapy for advanced gastric or gastroesophageal junction adenocarcinoma[J]. Clin Cancer Res, 2021, 27(11): 3069-3078. DOI: 10.1158/1078-0432.CCR-20-4691.

6. Kato K, Shah MA, Enzinger P, et al. KEYNOTE-590: Phase Ⅲ study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer[J]. Future Oncol, 2019, 15(10): 1057-1066. DOI: 10.2217/fon-2018-0609.

7. 唐浩淳，夏铮铮，左靖，等. 肿瘤患者免疫检查点抑制药用药安全性的回顾性研究[J]. 药物流行病学杂志, 2020, 29(5): 315-318, 323. [Tang HC, Xia ZZ, Zuo J, et al. A retrospective study on the safety of immunocheckpoint inhibition in cancer patients[J]. Chin J Pharmacoepidemiol, 2020, 29(5): 315-318, 323.] DOI: 10.19960/j.cnki.issn1005-0698.2020.05.004.

8. 李艳, 封卫毅, 毛维, 等. 应用德尔菲法构建抗肿瘤药物临床使用合理性评价指标体系[J]. 药学服务与研究, 2020, 20(6): 401-405. [Li Y, Feng WY, Mao W, et al. Establishment of the indicator system for clinical rationality evaluation of antitumor drugs by the Delphi method[J]. Pharm Care Res, 2020, 20(6): 401-405.] DOI: 10.5428/pcar20200601.

9. 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）食管癌诊疗指南2021[M]. 北京：人民卫生出版社，2021: 63-91.

10.李艳, 封卫毅, 仝敏, 等. 174例肺癌患者抗肿瘤药物应用评价分析[J]. 中南药学, 2020, 18(8): 1405-1409. [Li Y, Feng WY, Tong M, et al. Rational use of antineoplastic drugs in 174 lung cancer patients[J]. Central South Pharmacy, 2020, 18(8): 1405-1409.] DOI: 10.7539/j.issn.1672-2981.2020.08.025.

11.Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version1. 1)[J]. Eur J Cancer, 2008, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.

12.魏戌, 谢雁鸣. 国内外不良反应因果判断原则及评价方法解读[J]. 中国中药杂志, 2012, 37(18): 2744-2747. [Wei X, Xie YM. Principle of adverse drug reaction causality judgement and interpretation of causality assessment method both in China and abroad[J]. China Journal Chinese Materia Medica, 2012, 37(18): 2744-2747.] DOI: 10. 4268 /cjcmm20121819.

13.Parisi A, Palluzzi E, Cortellini A, et al. First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience[J]. Clin Transl Oncol, 2020, 22(1): 158-162. DOI: 10.1007/s12094-019-02122-x.

14.尤海生, 高乾, 高春侠, 等. 206例乳腺癌患者抗肿瘤药物应用评价分析[J]. 药物流行病学杂志, 2019, 28(8): 526-529, 542. [You HS, Gao Q, Gao CX, et al. Rational use analysis of antitumor drugs in 206 patients with breast cancer[J]. Chin J Pharmacoepidemiol, 2019, 28(8): 526-529, 542.] DOI: 10. 19960/j.cnki.issn1005-0698. 2019.08.008.

15.Nielson CM, Bylsma LC, Fryzek JP, et al. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis[J]. Oncologist, 2021, 26(9): e1609-e1618. DOI: 10.1002/onco.13822.

16.Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018, 24(6): 1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439.

17.Bang YJ, Kang YK, Catenacci DV, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase Ⅱ nonrandomized KEYNOTE-059 study[J]. Gastric Cancer, 2019, 22(4): 828-837. DOI: 10.1007/s10120-018-00909-5.

18.Yang W, Chang L, Guo Q, et al. Programmed cell death protein-1 inhibitors in the treatment of digestive system tumors in Chinese population: an observational study of effectiveness and safety[J]. Ann Palliat Med, 2021, 10(8): 9015-9024. DOI: 10.21037/apm-21-1827.

19.Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148. DOI: 10.1200/JCO.20.01888.